Liquid formulation for treatment of sickle cell now available

The EMA licensed liquid-form of hydroxycarbamide developed by pharmaceutical manufacturer Nova Laboratories is now available to sickle cell disease specialists in the UK and Ireland.

Set to revolutionise the control of sickle cell disease in children as young as two-years-old, the product Xromi is used to treat the disease and represents a significant evolution of solid dosage forms of the drug hydroxycarbamide that have been used in the treatment of sickle cell disease since the 1990s.

Xromi became available on prescription via the NHS on 23rd March 2020, and carries a two-year expiry date.

Granted a license by the European Medicines Agency (EMA) in July last year, and unveiled at the Annual Sickle Cell and Thalassaemia conference in London last October, Xromi is set to transform the control of sickle cell disease in young children because of its liquid form and strawberry flavour, which together make it easier for small children to take than the tablet form, as well as adolescents and adults with sickle cell disease who struggle to take tablets.

Dr Hussain Mulla, Head of Clinical Development at Nova Laboratories, explains: “Xromi is a new liquid formulation of hydroxycarbamide that makes administering the drug to children as young as two-years-old significantly easier and for the first time means doctors can personalise doses for young children.

“Nova Laboratories has invested £5.2m in Xromi’s intense four-year product development programme and trials of the liquid-form of the drug. We have also expanded our UK facility and global HQ in Leicestershire where Xromi is manufactured.”

He adds: “Xromi marks a new and major development in the treatment of sickle cell disease. We firmly believe that Xromi will significantly improve the lives of young patients suffering from the disease.”

Xromi is available on prescription-only to sick cell disease patients in the UK, EU and the Middle East through sickle cell disease healthcare specialists. Nova is planning for worldwide availability as soon as possible: “We have plans to reach the global market in order to help as many patients as possible to manage their symptoms and reduce vaso-occlusive complications,” says Dr Mulla.

Around 15,000 people in the UK suffer from sickle cell disease, 20 percent of whom are children under 16 years.

Hydroxycarbamide is a safe treatment modality and can boost foetal haemoglobin to levels that prevent red blood cells sickling and significantly reduce vaso-occlusive complications.

Dr Mulla adds: “The current pill form of hydroxycarbamide has been used in the treatment of sickle cell disease for more than 30 years. However, many children are not administered hydroxycarbamide until they develop serious acute or chronic clinical complications. Xromi is the first hydroxycarbamide formulation appropriate for young children, and as its liquid formula permits accuracy and precision, doctors can at last personalise doses in children.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Intravacc & Celonic to develop, produce novel COVID-19 vaccine

Intravacc, a Dutch viral and bacterial vaccine specialist, and Swiss CDMO, Celonic Group, have signed a research agreement to further design, develop and produce...

Tecentriq combination approved for advanced melanoma

The FDA has approved Roche’s Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety...

European approval for Novartis’ Cosentyx in paediatric psoriasis

Novartis has gained European approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The...

Hetero cleared to launch first remdesivir generic in India

Hetero, one of India’s leading generic pharmaceutical companies, has received the manufacturing and marketing approval for remdesivir from the Drug Controller General of India...

Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, has expanded its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell...

Related news

UK launches antibiotic buying scheme to tackle AMR

The NHS is launching a “pioneering scheme” to provide new antibiotics to patients by offering to pay pharma companies upfront for their work. The move...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Dyno launches to transform gene therapy using AI

Dyno Therapeutics, a Cambridge, Massachusetts-based biotech applying AI to gene therapy has officially launched from stealth mode with its proprietary platform, CapsidMap. The platform enables...

Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad Laboratories has launched a range of anti-certolizumab pegol inhibitory antibodies to support the development of assays for therapeutic drug monitoring of tumor necrosis...